MX2023006343A - 5'-o-fenilacetiluridina y uso terapeutico. - Google Patents

5'-o-fenilacetiluridina y uso terapeutico.

Info

Publication number
MX2023006343A
MX2023006343A MX2023006343A MX2023006343A MX2023006343A MX 2023006343 A MX2023006343 A MX 2023006343A MX 2023006343 A MX2023006343 A MX 2023006343A MX 2023006343 A MX2023006343 A MX 2023006343A MX 2023006343 A MX2023006343 A MX 2023006343A
Authority
MX
Mexico
Prior art keywords
phenylacetyluridine
therapeutic use
hepatic
phenylacetate
uridine
Prior art date
Application number
MX2023006343A
Other languages
English (en)
Spanish (es)
Inventor
Garcia Rolando Alejandro Garcia
Borstel Reid Warren Von
David Michael Simpson
Joel A Saydoff
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of MX2023006343A publication Critical patent/MX2023006343A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
MX2023006343A 2020-12-01 2021-11-30 5'-o-fenilacetiluridina y uso terapeutico. MX2023006343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119764P 2020-12-01 2020-12-01
PCT/US2021/061053 WO2022119784A1 (en) 2020-12-01 2021-11-30 5'-o-phenylacetyluridine and therapeutic use

Publications (1)

Publication Number Publication Date
MX2023006343A true MX2023006343A (es) 2023-06-12

Family

ID=81854225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006343A MX2023006343A (es) 2020-12-01 2021-11-30 5'-o-fenilacetiluridina y uso terapeutico.

Country Status (16)

Country Link
US (1) US20230416292A1 (https=)
EP (2) EP4255563B1 (https=)
JP (1) JP2023551467A (https=)
KR (1) KR20230112118A (https=)
CN (1) CN116782912A (https=)
AU (1) AU2021391411A1 (https=)
BR (1) BR112023010517A2 (https=)
CA (1) CA3199559A1 (https=)
DK (1) DK4255563T3 (https=)
FI (1) FI4255563T3 (https=)
IL (1) IL303100A (https=)
LT (1) LT4255563T (https=)
MX (1) MX2023006343A (https=)
PL (1) PL4255563T3 (https=)
PT (1) PT4255563T (https=)
WO (1) WO2022119784A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4210709T (pt) 2020-09-14 2026-02-04 Pharma Cinq Llc 2¿,3¿‐diacetiluridina substituída com acetoacetilo na posição 5¿
TW202317144A (zh) * 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
JP2526414B2 (ja) 1994-05-20 1996-08-21 工業技術院長 制ガン剤エステル化合物及びその製造方法
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP1808177B1 (en) * 1999-02-23 2018-08-08 The Regents of The University of California Methods of treatment of mitochondrial disorders
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
PL3182980T3 (pl) * 2014-08-19 2021-04-19 Wellstat Therapeutics Corporation Leczenie chorób niedoboru glikozylacji
AU2019215105B2 (en) * 2018-02-01 2024-12-19 Pharma Cinq, Llc Compositions and devices for systemic delivery of uridine
WO2022089612A1 (zh) * 2020-10-30 2022-05-05 上海岸阔医药科技有限公司 尿苷衍生物在制备药物中的应用

Also Published As

Publication number Publication date
PL4255563T3 (pl) 2026-04-20
EP4255563B1 (en) 2025-12-31
WO2022119784A1 (en) 2022-06-09
JP2023551467A (ja) 2023-12-08
AU2021391411A1 (en) 2023-07-20
IL303100A (en) 2023-07-01
EP4711007A2 (en) 2026-03-18
PT4255563T (pt) 2026-03-24
CN116782912A (zh) 2023-09-19
BR112023010517A2 (pt) 2024-02-06
KR20230112118A (ko) 2023-07-26
EP4255563A1 (en) 2023-10-11
FI4255563T3 (fi) 2026-03-13
EP4711007A3 (en) 2026-04-01
AU2021391411A9 (en) 2024-07-18
CA3199559A1 (en) 2022-06-09
EP4255563A4 (en) 2024-09-11
DK4255563T3 (da) 2026-03-16
LT4255563T (lt) 2026-04-10
US20230416292A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MX2023006343A (es) 5'-o-fenilacetiluridina y uso terapeutico.
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
MXPA05006670A (es) Administracion de capsaicinoides.
NZ778329A (en) Compositions of plinabulin and use thereof
JOP20190147A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PL1611088T3 (pl) Hydroksamiany jako środki terapeutyczne
MX348225B (es) Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
MX2022002686A (es) Cianopirrolidinas sustituidas con actividad como inhibidores de peptidasa 30 especifica de ubiquitina (usp30).
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
MX2023001717A (es) Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer.
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
EP1482959A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
HRP20110497T1 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
MX361741B (es) Tratamientos médicos a base de anamorelina.
ZA202212137B (en) N-cyanopyrrolidines with activity as usp30 inhibitors
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
ZA202213866B (en) N-cyanopyrrolidines with activity as usp30 inhibitors
MX2022010456A (es) Compuestos heterocíclicos para modular la subfamilia de receptores nucleares 2, grupo f, miembro 6.
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
EP3983533A4 (en) RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNESIGNALING STATES IN MYELOID MALIGNS VIA THE UBIQUITIN CONJUGATION ENZYME UBE2N
ZA202210111B (en) Anti-coronavirus effect and application of pi4k inhibitor
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol